文献速递糖尿病

胰高血糖素样肽1受体激动剂新使用者过敏反应风险:一项队列研究

Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
PubMed 文献 · Diabetes Care · 2024-01-01

本研究基于美国三个大型医疗保险索赔数据库(2017-2021年),纳入696,089例2型糖尿病成人GLP-1受体激动剂新使用者,评估过敏反应风险。随访期间过敏反应罕见,利司那肽队列发生率与其它GLP-1受体激动剂合并队列相比未达统计学显著差异(IRR 0.24,95%CI 0.01-1.35)。结论认为GLP-1受体激动剂相关过敏反应罕见,利司那肽不太可能比其他GLP-1受体激动剂带来更高的过敏反应风险。

要点

  • GLP-1受体激动剂新使用者中过敏反应罕见,各药物队列发生率均较低。
  • 利司那肽队列过敏反应发生率为每万人年1.0(95%CI 0.0-5.6)。
  • 利司那肽与其他GLP-1受体激动剂合并队列的过敏反应发生率比值无统计学显著差异。

核心结论

  • GLP-1受体激动剂相关过敏反应罕见,利司那肽不太可能比其他GLP-1受体激动剂带来更高的过敏反应风险。

研究设计与样本

  • 在美国三个大型医疗保险索赔数据库(2017-2021年)中开展的队列研究。
  • 纳入年龄≥18岁、患有2型糖尿病、在GLP-1受体激动剂启动前在数据库中有≥6个月参保记录的GLP-1受体激动剂新使用者。
  • 共纳入696,089例新使用者,累计暴露于GLP-1受体激动剂456,612人年。
  • 评估的药物包括利司那肽、甘精胰岛素/利司那肽固定比例复方制剂、艾塞那肽、利拉鲁肽或德谷胰岛素/利拉鲁肽固定比例复方制剂、度拉糖肽和司美格鲁肽(注射剂和口服剂)。

主要发现

  • 随访期间过敏反应发生率(每万人年,95%CI):利司那肽1.0(0.0-5.6),艾塞那肽6.0(3.6-9.4),利拉鲁肽5.1(3.7-7.0),度拉糖肽3.9(3.1-4.8),司美格鲁肽3.6(2.6-4.9)。
  • 利司那肽队列与其它GLP-1受体激动剂合并队列的过敏反应发生率比值(IRR)为0.24(95%CI 0.01-1.35),该分析为事后分析。
  • 各药物队列在基线人口学特征、合并症及索引日期前6个月内其他处方药使用方面相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on those starting lixisenatide therapy. RESEARCH DESIGN AND METHODS: A cohort study was conducted in three large, U.S. claims databases (2017-2021). Adult (aged ≥18 years) new users of a GLP-1 RA who had type 2 diabetes mellitus and ≥6 months enrollment in the database before GLP-1 RA initiation (start of follow-up) were included. GLP-1 RAs evaluated were lixisenatide, an insulin glargine/lixisenatide fixed-ratio combination (FRC), exenatide, liraglutide or insulin degludec/liraglutide FRC, dulaglutide, and semaglutide (injectable and oral). The first anaphylaxis event during follow-up was identified using a validated algorithm. Incidence rates (IRs) and 95% CIs were calculated within each medication cohort. The unadjusted IR ratio (IRR) comparing anaphylaxis rates in the lixisenatide cohort with all other GLP-1 RAs combined was analyzed post hoc. RESULTS: There were 696,089 new users with 456,612 person-years of exposure to GLP-1 RAs. Baseline demographics, comorbidities, and use of other prescription medications in the 6 months before the index date were similar across medication cohorts. IRs (95% CIs) per 10,000 person-years were 1.0 (0.0-5.6) for lixisenatide, 6.0 (3.6-9.4) for exenatide, 5.1 (3.7-7.0) for liraglutide, 3.9 (3.1-4.8) for dulaglutide, and 3.6 (2.6-4.9) for semaglutide. The IRR (95% CI) for the anaphylaxis rate for the lixisenatide cohort compared with the pooled other GLP-1 RA cohort was 0.24 (0.01-1.35). CONCLUSIONS: Anaphylaxis is rare with GLP-1 RAs. Lixisenatide is unlikely to confer higher risk of anaphylaxis than other GLP-1 RAs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Anthony MS, Aroda VR, Parlett LE, et al. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study. Diabetes Care. 2024. PMID: 38363873. doi:10.2337/dc23-1911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。